Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer
Geoff Chong(Austin Hospital), J Carmichael(Nottingham City Hospital), TM Cosgriff(University of New Orleans), Anish Bhatnagar(Titan Pharmaceuticals (United States)), Robert D. Hawkins(University of Manchester), Donald W. Northfelt(Mayo Clinic in Arizona), Robert E. Coleman(University of Sheffield), David Cunningham(Royal Marsden NHS Foundation Trust), Frank H. Valone(Titan Pharmaceuticals (United States)), J Cassidy(Cancer Research UK), John Bridgewater(University College London Hospitals NHS Foundation Trust), Sunil Sreedharan(Titan Pharmaceuticals (United States)), Charles H. Redfern(Sharp Memorial Hospital), Peter Harper(Fondazione IRCCS Istituto Nazionale dei Tumori), J Jones(Columbus Community Clinical Oncology Program), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), William P. Steward(University of Leicester), Malcolm J. Moore(University Health Network)
Cited by 32
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k